Abstracts tagged "Ankylosing spondylitis (AS) and extraarticular manifestations"

Abstract Number: 1544 • 2017 ACR/ARHP Annual Meeting
The Effect of Extraarticular Manifestations on Tumor Necrotic Factor α Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Nationwide Data from the Korean College of Rheumatology Biologics (KOBIO) Registry
Yunsuek Kim, Internal medicine, Soonchunhyang university Seoul hospital, Seoul, Korea, Republic of (South)
Background/Purpose: The tumor necrosis factor α inhibitor (TNFi) therapy has been shown to be remarkably effective in ankylosing spondylitis (AS). However, almost 30% of AS…
Abstract Number: 2775 • 2016 ACR/ARHP Annual Meeting
Conductive Hearing Loss Is Common in Ankylosing Spondylitis
Sajal Ajmani¹, Amit Keshri², Rakesh Srivastava² and Able Lawrence¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Neurosurgery (neuro-otology), Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis characterized by enthesitis, that primarily affects the spine and sacroiliac joints. While several studies had described…
Abstract Number: 2447 • 2013 ACR/ARHP Annual Meeting
Disease Activity Is Associated With Development Of Inflammatory Bowel Disease In Ankylosing Spondylitis: 12-Year Results From OASIS
Ivette Essers^1,2, Sofia Ramiro^3,4, Carmen Stolwijk^1,2, Robert Landewé^5,6, Désirée van der Heijde⁷, Filip van Den Bosch⁸, Maxime Dougados⁹ and Astrid Van Tubergen^1,2, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Atrium Medical Center, Heerlen, Netherlands, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ⁹Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France
Background/Purpose: Ankylosing spondylitis (AS) is associated with extra-articular manifestations (EAMs) such as acute anterior uveitis (AAU), inflammatory bowel disease (IBD), and psoriasis. Little is known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].